These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27681846)

  • 21. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The UK NEQAS for Molecular Genetics scheme for gastrointestinal stromal tumour: findings and recommendations following four rounds of circulation.
    Wong NA; Deans ZC; Ramsden SC
    J Clin Pathol; 2012 Sep; 65(9):786-90. PubMed ID: 22685257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.
    Ross JS
    Arch Pathol Lab Med; 2012 Oct; 136(10):1298-307. PubMed ID: 22272560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of RAS genes mutation using the Cobas
    Albertini AF; Raoux D; Neumann F; Rossat S; Tabet F; Pedeutour F; Duranton-Tanneur V; Kubiniek V; Vire O; Weinbreck N
    Bull Cancer; 2017; 104(7-8):662-674. PubMed ID: 28688743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
    Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
    Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress and potential of RAS mutation detection for diagnostics and companion diagnostics.
    Cree IA
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1067-1072. PubMed ID: 27494709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?
    Scott RJ; Fox SB; Desai J; Grieu F; Amanuel B; Garrett K; Harraway J; Cheetham G; Pattle N; Haddad A; Byron K; Rudzki B; Waring P; Iacopetta B
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):261-5. PubMed ID: 24811330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.
    Yoshino T; Muro K; Yamaguchi K; Nishina T; Denda T; Kudo T; Okamoto W; Taniguchi H; Akagi K; Kajiwara T; Hironaka S; Satoh T
    EBioMedicine; 2015 Apr; 2(4):317-23. PubMed ID: 26137573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.
    Tembuyser L; Ligtenberg MJ; Normanno N; Delen S; van Krieken JH; Dequeker EM
    J Mol Diagn; 2014 May; 16(3):371-7. PubMed ID: 24631467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.
    Udar N; Lofton-Day C; Dong J; Vavrek D; Jung AS; Meier K; Iyer A; Slaughter R; Gutekunst K; Bach BA; Peeters M; Douillard JY
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):2001-2010. PubMed ID: 30019318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.
    Cortes U; Guilloteau K; Rouvreau M; Archaimbault C; Villalva C; Karayan-Tapon L
    Exp Mol Pathol; 2015 Oct; 99(2):207-11. PubMed ID: 26163758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.
    Lovinfosse P; Koopmansch B; Lambert F; Jodogne S; Kustermans G; Hatt M; Visvikis D; Seidel L; Polus M; Albert A; Delvenne P; Hustinx R
    Br J Radiol; 2016 Jul; 89(1063):20160212. PubMed ID: 27146067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
    Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
    J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS mutation testing in colorectal cancer.
    Plesec TP; Hunt JL
    Adv Anat Pathol; 2009 Jul; 16(4):196-203. PubMed ID: 19546608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.
    Deans ZC; Bilbe N; O'Sullivan B; Lazarou LP; de Castro DG; Parry S; Dodson A; Taniere P; Clark C; Butler R
    J Clin Pathol; 2013 Apr; 66(4):319-25. PubMed ID: 23378269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma].
    Zhang K; Xu J; Yan L; Liu X; Xu F; Liu Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):254-7. PubMed ID: 25975908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.